In This Article:
Scotiabank lowered the firm’s price target on Sage Therapeutics (SAGE) to $12 from $14 and keeps an Outperform rating on the shares. The firm’s rating remains Outperform based on its belief that the company will be sold to Biogen (BIIB) at a significant premium, the analyst tells investors.
Maximize Your Portfolio with Data Driven Insights:
-
Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
-
Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SAGE:
-
Sage Therapeutics price target lowered to $7 from $9 at Baird
-
Cautious Outlook on SAGE Therapeutics Amid Strategic Uncertainty and Pipeline Ambiguities
-
Sage Therapeutics price target lowered to $8 from $9 at Canaccord
-
SAGE Therapeutics: Hold Rating Amid Uncertainty and Strategic Exploration
-
Hold Rating on SAGE Therapeutics Amid Underwhelming Sales and Strategic Uncertainties